Clean Label Project to Showcase Latest Protein Powder Contaminant Study at Natural Products Expo West 2025
DENVER, CO, UNITED STATES, March 4, 2025 / EINPresswire.com / -- Clean Label Project (CLP), a nonprofit organization committed to transparency in consumer product labeling and ingredient quality, will be exhibiting at Natural Products Expo West 2025, the leading trade show for the natural and organic products industry. Attendees are invited to visit the Clean Label Project Booth 3195 to learn more about the latest findings from CLP's Protein Investigation 2.0 study, which identified elevated levels of heavy metals in popular protein powders.
As consumers increasingly incorporate protein supplements into their wellness routines and turn to GLP-1s for weight management, Clean Label Project's research offers vital insights into ingredient sourcing, manufacturing practices, and potential risks tied to some of the market's most popular products.
Protein Investigation 2.0: Key Findings
Clean Label Project's analysis of 160 protein supplements, representing 83% of the market share, revealed:
- 77% of protein powders tested contained lead, with nearly half exceeding California's Prop 65 safety limits in one serving.
- Organic protein powders contained three times more lead and twice as much cadmium as non-organic varieties.
- Chocolate-flavored protein powders contained up to 110 times more cadmium than vanilla-flavored powders.
CLP's 'Clean Sixteen'
Clean Label Project is excited to unveil our 'Clean Sixteen' — a lineup of sixteen protein powders that tested non-detect for heavy metals in the 2024/2025 protein powder study. This achievement highlights that, with dedicated supply chain diligence, it's entirely possible to craft protein powders that are not only nutritious, affordable, and delicious but also low in heavy metals.
Visit Clean Label Project at Expo West 2025
'Protein powder plays a key role in the morning routines of those aiming to build muscle, shed weight, or enhance their healthy lifestyle,' said Jackie Bowen, Executive Director of Clean Label Project. 'Consumers have a right to transparency about the products they rely on for their health. At Expo West, we're excited to explore how brands can elevate safety standards, refine sourcing practices, and restore consumer trust.'
Booth #3195 – Stop by to learn more about Clean Label Project's certification programs, industry advocacy efforts, and the latest contaminant testing insights.
For more information on Clean Label Project's latest research and initiatives, visit www.cleanlabelproject.org.
About Clean Label Project
Clean Label Project is a nonprofit organization dedicated to promoting truth and transparency in consumer product labeling and ingredient quality. Through independent testing for industrial and environmental contaminants, Clean Label Project provides consumers with the data they need to make informed, healthier choices.
Kate Stuard
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Weight loss jabs linked to potentially fatal side effects, says new report
Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting health officials to launch a new study into side effects. Some cases of pancreatitis reported to be linked to GLP-1 medicines (glucagon-like peptide-1 receptor agonists) have been fatal. Data from the medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), shows that since the drugs were licensed there have been hundreds of cases of acute and chronic pancreatitis among people taking GLP-1 medicines. The new weight management medication 'Tirzepatide' (brand name Mounjaro®) is shortly being made available to NHS patients to support weight loss. Access is prioritised for those with the greatest clinical need. You can find out more at: — NHS Cheshire and Merseyside (@NHSCandM) June 24, 2025 This includes: 181 reported cases of acute and chronic pancreatitis linked to tirzepatide – the active ingredient for Mounjaro. Five people died. 116 reported reactions of this kind linked to liraglutide, one of which was fatal. 113 cases of acute and chronic pancreatitis linked to semaglutide – the active ingredient for Ozempic and Wegovy. One person died. 101 reported reactions of this kind linked to exenatide, three people died. 52 reported reactions of this sort linked to dulaglutide and 11 reported reactions lixisenatide. No fatalities were linked to either drug. These cases are not confirmed as being caused by the medicines, but the person who reported them suspected they may be. Review your ICB's local policy about treating patients with tirzepatide (Mounjaro) for weight management in a primary care setting and visit: — We are Primary Care (@PrimaryCareNHS) June 27, 2025 Nonetheless, Yellow Card Biobank project, launched by the MHRA and Genomics England, will see researchers examine whether cases of pancreatitis linked to GLP-1 drugs may be influenced by peoples genetic makeup. The MHRA is calling for people who are taking GLP-1 medicine who have been admitted to hospital due to acute pancreatitis to submit a report to its Yellow Card scheme. When a Yellow Card report is received, the MHRA will contact patients to ask if they would be willing to take part in the study. Patients will be asked to submit more information and a saliva sample which will be assessed to explore whether some people are at a higher risk of acute pancreatitis when taking these medicines due to their genes. GLP-1 agonists can lower blood sugar levels in people living with type 2 diabetes and can also be prescribed to support some people with weight loss. 🧵Weight loss jab roll out 'positive for patients' but with implications for general practice that must be considered. Our Chair Kamila Hawthorne has featured widely in the national press and broadcast media responding to the phased roll-out of Mounjaro prescriptions by NHS… — Royal College of General Practitioners (@rcgp) June 23, 2025 Chronic stress and poor sleep are major weight loss blockers. Stress increases cortisol, a hormone linked to fat retention, especially around the abdomen. Sleep deprivation increases ghrelin (hunger hormone) and decreases leptin (fullness hormone), making you more likely to overeat and less likely to move. You're also more impulsive and less motivated when sleep-deprived, making it harder to stick to your diet and exercise routine. As a solution, prioritise stress management techniques (like mindfulness or journaling), and aim for 7-9 hours of sleep per night. Medical issues such as PCOS, diabetes, hypothyroidism, or insulin resistance can all interfere with weight loss. Similarly, certain medications (like antidepressants or steroids) may cause weight gain or inhibit fat loss. If weight loss stalls despite doing everything right, consult your GP to rule out or address any underlying conditions. If you have a known medical condition, it's important to stay up to date with your routine reviews and inform your GP or specialist about any weight loss treatments you're using. Regular follow-up helps ensure your treatment plan remains safe and effective. More Mounjaro news... Who is eligible for Mounjaro on the NHS? Urgent holiday warning for Mounjaro users issued Mounjaro warning as summer temperatures rise Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs. Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects. Most side effects linked to the jabs are gastrointestinal including nausea, constipation and diarrhoea. And the medical regulator recently warned that Mounjaro may make the oral contraceptive pill less effective in some patients. Dr Alison Cave, MHRA's chief safety officer, said: 'Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone. 'Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions – enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup. 'To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme. 'Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety.' Professor Matt Brown, chief scientific officer of Genomics England, said: 'GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects. 'We believe there is real potential to minimise these with many adverse reactions having a genetic cause. 'This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system.'
Yahoo
a day ago
- Yahoo
Metabolics Pharma Announces ENT-03 Generates Sustained Weight Loss and Liver Pathology Improvements in an Animal Model for Obesity
DOYLESTOWN, Pa., June 27, 2025--(BUSINESS WIRE)--Metabolics Pharma ("Metabolics"), a privately held, Doylestown-based, clinical-stage biopharmaceutical company pioneering novel treatments for metabolic diseases, today announced that its drug candidate, ENT-03, showed significant benefit in metabolic dysfunction in addition to sustaining weight loss, improvement in blood glucose, and insulin sensitivity in comparison to semaglutide in an animal model for obesity. "Metabolics Pharma spun off from its parent company, Enterin, in late 2024 so that the company could focus its efforts on and enhance the value of its lead asset, ENT-03, for the treatment of obesity and certain comorbidities," said Richard Larson, M.D., Ph.D., Chief Executive Officer, Chief Medical Officer and Board Chairman of Metabolics Pharma. "These preclinical data highlight both the promise and potential value of ENT-03 in the treatment of metabolic disease. The research shows that ENT-03 clearly improves insulin sensitivity and sustained weight reduction that persists following cessation of treatment. This research is the foundation for our Phase 1 clinical trials in healthy obese and diabetic obese subjects." ENT-03 is a novel, centrally acting aminosterol with Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, which normalizes glucose and causes weight loss by acting on brain circuits that regulate energy and metabolism. In obese, diabetic mice, ENT-03 rapidly lowers blood glucose, reduces food intake and adiposity, eliminates liver fat, and improves liver function. This study compared ENT-03 to semaglutide, a combination of the two compounds, and vehicle in Diet Induced Obesity (DIO) mice. While the vehicle-treated mice gained weight through the duration of the study, mice treated with ENT-03, Semaglutide, or a combination of the two drugs all lost weight and reduced insulin and glucose levels. ENT-03 showed a greater reduction in weight than Semaglutide over the 10-week treatment period. Additive weigh loss was seen when the drugs were used in combination. After cessation of therapy, weight loss and reduction in glucose and insulin were sustained for an additional two months in the ENT-03 treated mice but not Semaglutide treated mice. In addition, ENT-03 showed substantially greater preservation of lean mass in comparison to other treatment groups. "GLP-1 agonists have revolutionized the treatment of obesity and type 2 diabetes," said Richard Larson, MD, PhD. "However, their impressive efficacy comes at the price of tolerability challenges, the loss of lean body mass, and the need to remain on treatment to sustain weight loss. ENT-03 represents a novel drug candidate that could be an alternative treatment to GLP-1 agonists or used in combination with them. We believe that ENT-03 could have a substantial impact on the obesity drug market since it has potential benefits beyond weight loss." Metabolics Pharma has completed a Phase 1a, first in human, randomized, double-blind, single ascending dose study of ENT-03. Results of the Phase 1a trial were presented at the American Diabetes Association 85th Scientific Sessions on June 22, 2025. A Phase 1b clinical trial is planned to initiate in the second half of 2025. About Metabolics Pharma Metabolics Pharma develops novel therapies for the treatment of metabolic diseases including obesity and type 2 diabetes. The Company's lead compound, ENT-03, in development for the treatment of type 2 diabetes and obesity, increases insulin sensitivity by acting at the level of the brain. ENT-03 has completed a Phase 1a clinical trial and will begin a Phase 1b clinical trial in the second half of 2025. For more information, please visit View source version on Contacts Richard Larson, M.D., Executive Officer, Chief Medical Officer, and Chairman of the Board John DessoukiChief Financial Sign in to access your portfolio
Business Wire
a day ago
- Business Wire
Metabolics Pharma Announces ENT-03 Generates Sustained Weight Loss and Liver Pathology Improvements in an Animal Model for Obesity
DOYLESTOWN, Pa.--(BUSINESS WIRE)--Metabolics Pharma ('Metabolics'), a privately held, Doylestown-based, clinical-stage biopharmaceutical company pioneering novel treatments for metabolic diseases, today announced that its drug candidate, ENT-03, showed significant benefit in metabolic dysfunction in addition to sustaining weight loss, improvement in blood glucose, and insulin sensitivity in comparison to semaglutide in an animal model for obesity. 'Metabolics Pharma spun off from its parent company, Enterin, in late 2024 so that the company could focus its efforts on and enhance the value of its lead asset, ENT-03, for the treatment of obesity and certain comorbidities,' said Richard Larson, M.D., Ph.D., Chief Executive Officer, Chief Medical Officer and Board Chairman of Metabolics Pharma. 'These preclinical data highlight both the promise and potential value of ENT-03 in the treatment of metabolic disease. The research shows that ENT-03 clearly improves insulin sensitivity and sustained weight reduction that persists following cessation of treatment. This research is the foundation for our Phase 1 clinical trials in healthy obese and diabetic obese subjects.' ENT-03 is a novel, centrally acting aminosterol with Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, which normalizes glucose and causes weight loss by acting on brain circuits that regulate energy and metabolism. In obese, diabetic mice, ENT-03 rapidly lowers blood glucose, reduces food intake and adiposity, eliminates liver fat, and improves liver function. This study compared ENT-03 to semaglutide, a combination of the two compounds, and vehicle in Diet Induced Obesity (DIO) mice. While the vehicle-treated mice gained weight through the duration of the study, mice treated with ENT-03, Semaglutide, or a combination of the two drugs all lost weight and reduced insulin and glucose levels. ENT-03 showed a greater reduction in weight than Semaglutide over the 10-week treatment period. Additive weigh loss was seen when the drugs were used in combination. After cessation of therapy, weight loss and reduction in glucose and insulin were sustained for an additional two months in the ENT-03 treated mice but not Semaglutide treated mice. In addition, ENT-03 showed substantially greater preservation of lean mass in comparison to other treatment groups. 'GLP-1 agonists have revolutionized the treatment of obesity and type 2 diabetes,' said Richard Larson, MD, PhD. 'However, their impressive efficacy comes at the price of tolerability challenges, the loss of lean body mass, and the need to remain on treatment to sustain weight loss. ENT-03 represents a novel drug candidate that could be an alternative treatment to GLP-1 agonists or used in combination with them. We believe that ENT-03 could have a substantial impact on the obesity drug market since it has potential benefits beyond weight loss.' Metabolics Pharma has completed a Phase 1a, first in human, randomized, double-blind, single ascending dose study of ENT-03. Results of the Phase 1a trial were presented at the American Diabetes Association 85 th Scientific Sessions on June 22, 2025. A Phase 1b clinical trial is planned to initiate in the second half of 2025. About Metabolics Pharma Metabolics Pharma develops novel therapies for the treatment of metabolic diseases including obesity and type 2 diabetes. The Company's lead compound, ENT-03, in development for the treatment of type 2 diabetes and obesity, increases insulin sensitivity by acting at the level of the brain. ENT-03 has completed a Phase 1a clinical trial and will begin a Phase 1b clinical trial in the second half of 2025. For more information, please visit
